CERADON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CERADON is a small-molecule injectable drug approved in 1988 by Takeda. Mechanism of action and specific indication are not publicly disclosed in available data. The product is administered via injection.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting team contraction and transition to generic/lifecycle management roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CERADON offers limited career growth given its LOE-approaching lifecycle and zero linked job openings. Roles focus on defensive commercial execution and transition planning rather than innovation.
Brand ManagerField Sales Representative
Worked on CERADON at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.